JP5149789B2 - Ｖｙｇｆｖｒａｃｌ−ｈｌａ−ａ２４に特異的に結合するｔ細胞レセプター - Google Patents

Ｖｙｇｆｖｒａｃｌ−ｈｌａ−ａ２４に特異的に結合するｔ細胞レセプター Download PDF

Info

Publication number
JP5149789B2
JP5149789B2 JP2008512901A JP2008512901A JP5149789B2 JP 5149789 B2 JP5149789 B2 JP 5149789B2 JP 2008512901 A JP2008512901 A JP 2008512901A JP 2008512901 A JP2008512901 A JP 2008512901A JP 5149789 B2 JP5149789 B2 JP 5149789B2
Authority
JP
Japan
Prior art keywords
tcr
seq
chain
hla
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008512901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009506753A5 (enExample
JP2009506753A (ja
Inventor
ヤコブセン，ベント，カルステン
リー，イ
Original Assignee
イムノコア リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2005/002078 external-priority patent/WO2005116646A1/en
Application filed by イムノコア リミテッド filed Critical イムノコア リミテッド
Priority claimed from PCT/GB2006/001857 external-priority patent/WO2006125962A2/en
Publication of JP2009506753A publication Critical patent/JP2009506753A/ja
Publication of JP2009506753A5 publication Critical patent/JP2009506753A5/ja
Application granted granted Critical
Publication of JP5149789B2 publication Critical patent/JP5149789B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2008512901A 2005-05-25 2006-05-19 Ｖｙｇｆｖｒａｃｌ−ｈｌａ−ａ２４に特異的に結合するｔ細胞レセプター Expired - Fee Related JP5149789B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2005/002078 WO2005116646A1 (en) 2004-05-26 2005-05-25 Method for the identification of a polypeptide which binds to a given pmhc complex
GBPCT/GB2005/002078 2005-05-25
GBGB0524477.7A GB0524477D0 (en) 2005-11-30 2005-11-30 Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0524477.7 2005-11-30
PCT/GB2006/001857 WO2006125962A2 (en) 2005-05-25 2006-05-19 T cell receptors which specifically bind to vygfvracl-hla-a24

Publications (3)

Publication Number Publication Date
JP2009506753A JP2009506753A (ja) 2009-02-19
JP2009506753A5 JP2009506753A5 (enExample) 2009-07-02
JP5149789B2 true JP5149789B2 (ja) 2013-02-20

Family

ID=35685841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008512901A Expired - Fee Related JP5149789B2 (ja) 2005-05-25 2006-05-19 Ｖｙｇｆｖｒａｃｌ−ｈｌａ−ａ２４に特異的に結合するｔ細胞レセプター

Country Status (8)

Country Link
US (1) US8017730B2 (enExample)
EP (1) EP1885754B1 (enExample)
JP (1) JP5149789B2 (enExample)
CN (1) CN101389652B (enExample)
AT (1) ATE497976T1 (enExample)
DE (1) DE602006020037D1 (enExample)
ES (1) ES2360598T3 (enExample)
GB (1) GB0524477D0 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
NZ741124A (en) * 2012-07-27 2019-11-29 Univ Illinois Engineering t-cell receptors
DK2971045T3 (da) * 2013-03-13 2019-09-16 Health Research Inc Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen
JP6476182B2 (ja) 2013-11-22 2019-02-27 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 改変された高親和性ヒトｔ細胞受容体
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201516277D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
CN106632660B (zh) * 2015-11-04 2021-01-29 广东香雪精准医疗技术有限公司 识别ny-eso-1抗原短肽的tcr
EP4357454A3 (en) * 2016-03-16 2024-07-24 Immatics Biotechnologies GmbH Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
CN107987155A (zh) * 2016-10-27 2018-05-04 中国科学院广州生物医药与健康研究院 识别sage1抗原短肽的t细胞受体
CN109251243B (zh) * 2017-07-13 2021-10-19 中国科学院广州生物医药与健康研究院 一种识别sage1抗原的t细胞受体及编码该受体的核酸
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759243B2 (en) * 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
PT1421115E (pt) * 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
DK1758935T3 (da) * 2004-05-26 2009-08-10 Immunocore Ltd Telomerase-T-cellereceptorer med höj affinitet
GB0427585D0 (en) 2004-12-16 2005-01-19 Avidex Ltd Assay

Also Published As

Publication number Publication date
US20080292602A1 (en) 2008-11-27
CN101389652A (zh) 2009-03-18
EP1885754B1 (en) 2011-02-09
DE602006020037D1 (de) 2011-03-24
GB0524477D0 (en) 2006-01-11
ATE497976T1 (de) 2011-02-15
CN101389652B (zh) 2013-05-29
US8017730B2 (en) 2011-09-13
JP2009506753A (ja) 2009-02-19
EP1885754A2 (en) 2008-02-13
ES2360598T3 (es) 2011-06-07

Similar Documents

Publication Publication Date Title
JP4773434B2 (ja) 高親和性ｎｙ−ｅｓｏｔ細胞受容体
CN101189261B (zh) 高亲和力Melan-A T细胞受体
JP5885220B2 (ja) 高親和性ｈｉｖｔ細胞レセプター
WO2006125962A2 (en) T cell receptors which specifically bind to vygfvracl-hla-a24
JP2006523437A (ja) レセプター複合体
US8017730B2 (en) T cell receptors which specifically bind to VYGFVRACL-HLA-A24
WO2017076308A1 (zh) 识别ny-eso-1抗原短肽的tcr
JP2008520227A (ja) 可溶性二官能性タンパク質
JP5186209B2 (ja) テロメラーゼ高親和性ｔ細胞受容体
CN1989153B (zh) 高亲和力ny-eso t细胞受体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090514

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121130

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151207

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees